INTRODUCTION
The integrity of the articular cartilage is maintained by a wellbalanced metabolism of the matrix components. Under physiological conditions, the turnover of collagen and proteolglycans seems to be very low (Maroudas, 1975) . In degenerative and inflammatory disease such as osteoarthritis or rheumatoid arthritis a disturbance of this metabolic balance occurs, resulting in a dramatic increase in proteolysis. The catabolism far exceeds the ability of the chondrocytes to increase the rate of matrix synthesis in order to compensate for the increased loss of matrix molecules. Among the various enzymes capable of degrading matrix components, neutral proteinases of the metallo-and serine type seem to be of major importance for the initiation of matrix breakdown in the extracellular compartment (Barrett, 1978) . Polymorphonuclear leucocytes (PMN), which are abundant in effusions of inflamed joints, contain three of these proteinases: elastase, cathepsin G and collagenase (Baggiolini et al., 1978) . In the synovial fluid the destructive potential of these enzymes is normally controlled by the anti-proteinase potential of serum inhibitors, e.g. ax-proteinase inhibitor (a1-PI) or a2-macroglobulin (a2-M). However, a local disturbance of the enzymeinhibitor balance may occur and promote tissue destruction (Burkhardt et al., 1987) . Therefore low-Mr proteinase inhibitors within the tissue itself may be even more important in the regulation of matrix turnover. The tissue inhibitor of metalloproteinases (TIMP), which was originally purified from rabbit bones (Cawston et al., 1981) , was shown to be synthesized by chondrocytes in culture (Duncan & Reynolds, 1983) . Its synthesis is affected by growth factors such as transforming growth factor ,t (TGF/J; Edwards et al., 1987) .
TIMP has been cloned (Docherty et al., 1985) and seems to exist in two different forms, namely TIMP 1 and TIMP 2 (Stetler-Stevenson et al., 1989) . The information concerning serine-proteinase-inhibitory activity in articular cartilage is far less complete. Since Kuettner et al. (1974) and Sorgente et al. (1975) reported on a cationic protein from bovine cartilage with trypsin-inhibitory activity and an apparent Mr of 13 000, several workers (Roughley et al., 1978; Killackey et al,, 1983; Lesjak & Ghosh 1984) have confirmed the presence of serine-proteinaseinhibitory activity in cartilage of different origin, but failed to characterize the isolated molecules responsible for this activity. In a previous paper (Burkhardt et al., 1987) we briefly summarized the conflicting data in more detail and reported on the partial purification and characterization of a serine-proteinase inhibitor from human articular cartilage. In the present paper we describe a modified purification scheme that permits us to separate the inhibitor from contaminating lysozyme and the identification of the inhibitor molecule as a homologue of the acid-stable proteinase inhibitor of human mucous secretions.
MATERIALS AND METHODS Enzymes
Cathepsin G (EC 3.4.21.20) was purified from buffy coats of healthy blood donors according to the method of Engelbrecht et al. (1982) . Trypsin (bovine pancreas) was purchased from Serva (Heidelberg, Germany) and elastase (EC 3.4.21.37) from Elastin Products (Owensville, MO, U.S.A.).
Assays
Elastase-inhibitory activity was measured using methoxysuccinyl (MeO-Suc)-Ala-Ala-Pro-Val-4-nitroanilide (4NA) (Najajima et al., 1979) as chromogenic substrate. Trypsin inhibition was assayed by the method of Erlanger et al. (1961) , employing benzoyl-DL-Arg-4NA. Suc-Phe-Pro-Phe-4NA was used to determine cathepsin G activity (Woodbury & Yoshida et al., 1980) . All assays were commenced after 15 min preincubation of the inhibitor probe with the enzyme.
Cartilage extraction
Human articular cartilage was taken for the knee joints of adolescent trauma victims within 24 h post mortem. From this starting material the inhibitor fractions were extracted by using a previously published protocol (Burkhardt et al., 1987) . Briefly, after extensive washing in normal saline and mechanical fractionation, the cartilage homogenate was stirred for 48 h at 4 'C in 200 mM-Tris/HCl (pH 7.4)/0.5 M-NaCl/50 mM-CaCl2/ 2 M-guanidinium chloride/0.05 % (v/v) Brij 35. After centrifugation at 48000 g at 4°C for 30 min the supernatant was filtered through an Amicon XM 100 membrane to remove large proteoglycans.
Ion-exchange chromatography
The cartilage extract was dialysed against 0.05 M-acetate buffer, pH 5.5, and applied to a CM-cellulose column (CM-52; Whatman; 2.8 cm x 45 cm) equilibrated with same buffer. The proteins were eluted with a linear increasing gradient of 0-1 M-NaCl and collected in 7 ml fractions.
A portion of the inhibitor fractions was re-equilibrated with the starting buffer (0.05 M-acetate, pH 5.5) and subjected to f.p.l.c. on a Mono S column (Pharmacia). The column was eluted under a pressure of 2 MPa using a linear gradient between 0 and 1 M-NaCl over 50 ml.
Affinity chromatography
Another portion of the inhibitor fractions eluted from the CM-52 column was equilibrated with 0.05 M-Tris/HCl (pH 8.2)/0.02 M-CaC12 and applied to 1 ml of trypsin-Sepharose (Sigma). After an incubation period of 1 h at room temperature, the Sepharose was washed with 50 ml of buffer. Elution of protein bound to trypsin-Sepharose was performed by the addition of 2 ml of buffer containing 10 mg of the specific irreversible trypsin inhibitor N-a-p-tosyl-L-lysylchloromethane hydrochloride (Tos-Lys-CH2Cl) ('TLCK'; Bissendorf, Hannover, Germany).
Reverse-phase chromatography
In the last step of the purification procedure the inhibitor fractions were subjected to h.p.l.c. on a Vydac C18 reverse-phase column. After concentration in a Speed-Vac centrifuge (Bachhofer, Reutlingen, Germany) the probes were dissolved in 500 ,ul of 0.1 0% trifluoroacetic acid (TFA) and loaded on to the column. For the mobile phase a gradient system of acetonitrile (0-100 %) in 0.08 % TFA was chosen.
Homogeneity of the peptides was controlled by SDS/PAGE in 180% -(w/v)-acrylamide Minigels using the buffer system described by Laemmli (1970) . Gels were stained with Coomassie Blue or silver as described by Oakley et al. (1980) .
Western blot
After electrophoresis the cartilage-derived inhibitor and a sample of recombinant-derived acid-stable inhibitor of mucous secretions were blotted on to nitrocellulose filters (Towbin et al., 1979) . After blocking with low-fat milk protein, the blotted proteins were immunolabelled with a specific rabbit antibody to the recombinant-derived mucous inhibitor [antibody dilution 1: 1000 in phosphate-buffered saline (PBS)], using peroxidaselabelled goat anti-rabbit IgG (Bio-Rad Laboratories) as second antibody, and chloronaphthol as colour substrate. The recombinant-derived inhibitor and the specific rabbit antibody were generously given by Dr. R-. Heinzel-Wieland (Griinenthal G.m.b.H., Stolberg, Germany).
Affinity blotting
For the identification of protein bands with PMN elastase binding capacity in the beginning of the purification procedure, we applied a modified Western-blot technique. Using conventional blotting (Towbin et al., 1979) and blocking with low-fat milk protein, the nitrocellulose filters were incubated with 15 ,ug of PMN elastase in 5 ml of PBS for 2 h at room temperature. After thorough washing with PBS and a second blocking step, the blot was immunolabelled with a sheep anti-(PMN elastase) antibody (Serotec, Oxford, UK), followed by peroxidase-labelling rabbit anti-sheep IgG (Dianova, Hamburg, Germany). Chloronaphthol was employed as colour substrate.
Amino acid sequencing
The amino acid sequence was determined on a gas-phase sequencer (Applied Biosystems).
RESULTS
After guanidinium hydrochloride extraction and ultrafiltration, the inhibitor fractions were applied on CM-52 and eluted from the ion-exchange column at NaCl concentrations between 0.5 and 0.6 M. The chromatographic profile is shown in Fig. 1 . The eluted fractions show one main inhibitory peak, with maximal inhibition values of 100 % for trypsin (60 munits/ml), PMN elastase (2 munits/ml) and cathepsin G (6 munits/ml).
SDS/PAGE revealed that this fraction was still heterogenous, containing lysozyme as the main impurity (Fig. 2) .
In order to identify protein bands with inhibitory activity, we established a modified Western-blot technique. After conventional blotting (Towbin et al., 1979) and blocking with low-fat milk protein, the nitrocellulose filters were incubated with PMN elastase. After thorough washing with PBS and a second blocking step, the blot was immunolabelled with an anti-(PMN elastase) sheep antibody, followed by peroxidase-labelled rabbit anti-sheep IgG. This technique revealed elastase-binding protein bands corresponding to an apparent molecular mass of 16 kDa after electrophoresis of the non-reduced fractions with inhibitory activity (Fig. 2) .
Final purification was hampered by the difficulty in separating the inhibitor molecule from the lysozyme contamination. Two different strategies were followed. In a first attempt batch adsorption to trypsin-Sepharose was tested. After adsorption to Fig. 3 . Reverse-phase h.p.l.c. of the inhibitor after affinity purification on trypsin-Sepharose After elution from the trypsin-Sepharose column the inhibitor fractions were applied on a Vydac C18 reverse-phase column. Elution was achieved by a linear gradient (straight diagonal line) of acetonitrile of 5-1000% in 0.08 % TFA (see the Materials and methods section). The inhibitor was eluted in the main fraction after 37 min. found in the eluate. However, subsequent washing with buffer containing the trypsin inhibitor Tos-Lys-CH2CI eluted the elastase-inhibitory activity. In preliminary experiments a direct effect of Tos-Lys-CH2Cl on PMN elastase activity had been excluded. Therefore a fraction was identified which is capable of binding to trypsin-Sepharose in a reversible manner. Moreover, after removal from trypsin by a competitor which binds to the active centre of the enzyme irreversibly, this fraction still exhibits inhibitory activity towards PMN elastase. SDS/PAGE revealed that the inhibitor sample was still heterogeneous, though a progression in purification was achieved (results not shown). Therefore subsequent reverse-phase h.p.l.c. was performed. As shown in Fig. 3 , at 37% acetonitrile a sharp peak was eluted from the Vydac C15 column, which was subjected to amino acid sequencing. Four main sequences were identified: from the Nterminus, six residues were identified, starting at position 4. Comparison of these partial sequence data with known serineproteinase inhibitors gave a hint to a relationship of the cartilagederived inhibitor to human secretory leucocyte proteinase inhibitor (SLPI) ( Table 1) . Therefore we interpreted the four main sequences as a result of partial proteolysis of the inhibitor on the trypsin-Sepharose column, while intramolecular disulphide bridges keep the molecule together. As attempts to obtain unequivocal sequence data after reduction and carboxymethylation failed, the purification strategy was changed.
After ion-exchange chromatography on CM52 we used a Mono S cation-exchange column for rechromatography of the inhibitor fractions. As shown in Fig. 4 , two main peaks were eluted with a salt gradient. The minor peak exhibited elastaseinhibitory activity. This fraction was subjected to reverse-phase h.p.l.c. on a Vydac C18 column. At 37 % acetonitrile a fraction was eluted from the column that inhibited PMN elastase. This fraction proved to be homogeneous by silver staining after SDS/PAGE (Fig. 5 ). It migrated with the same electrophoretic mobility as the recombinant SLPI and cross-reacted in Western blot with a specific rabbit antibody to the recombinant-derived mucous inhibitor (Fig. 5) .
The amino acid sequence analysis of the N-terminal 24 amino acid residues was determined by gas-phase sequencing (Table 2) . Comparison with the SLPI molecule (Table 2) demonstrated identity with SLPI in 22 residues out of a total of 24 residues. For positions 10 and 18 the identification of the amino acids failed. In both positions there is a cysteine residue in the SLPI sequence.
The major peak from the Mono S column was subsequently
Vol. 274 Position... 1 2 3 4 5 6 7 8 9 10
Position... 11 12 13 14 15 16 17 18 19 20
subjected to reverse-phase h.p.l.c. The peak eluted at 45 % acetonitrile was sequenced and identified as a homologue ofchick lysozyme in the nine N-terminal residues analysed (sequence: KVFERELA).
DISCUSSION
Since the first reports of the presence of a serine-proteinase inhibitor in cartilage tissue (Kuettner et al., 1974; Sorgente et al., 1975) , conflicting data have been published on the nature of the molecule responsible for this activity (Roughley et al., 1978; Killakey et al., 1983; Lesjak & Ghosh, 1984) . In a previous paper (Burkhardt et al., 1987) we reported on the partial purification and characterization of the inhibitor and briefly reviewed the discrepancies found in the literature. More recently DiMuzio et al. (1987) (Thompson & Ohlsson, 1986 (Burkhardt et al., 1987; Thompson & Ohlsson, 1986 ) has been described (pI > 10); (3) the acid-resistance of the cartilagederived inhibitor is proven by the fact that elastase inhibition is still detectable after reverse-phase chromatography in 0.1% TFA; (4) on SDS/PAGE the reduced cartilage inhibitor migrated together with the recombinant-derived mucous inhibitor in a very short distance above the lysozyme marker band (Fig. 5) .
The aberrant electrophoretic mobility of SLPI on SDS/PAGE compared with Mrcalculation on the basis of the known sequence (11726) was related to its cationic nature (Thompson & Ohlsson, 1986) ; (5) a specific antibody to the recombinant-derived SLPI cross-reacts with the cartilage inhibitor in the immunoblot (Fig. 5) .
The existence of only one inhibitor of this type is supported by the literature, as there is no evidence for a genetic divergence of SLPI-related proteinase inhibitors. Some closely related inhibitors from different mucous secretions, which had been originally regarded as distinct proteins, were in fact proven to be identical with SLPI: cervix uteri secretion inhibitor ('CUSI') , HUSI-I (Seemuller et al., 1986) and bronchial leukocyte proteinase inhibitor ('BLPI') (Boudier et al., 1988) . Moreover, the SLPI gene was shown to be a single-copy gene (Stetler et al., 1986) .
In contrast with the reported exclusive detection in mucous secretions, our data are the first evidence for an additional role of the SLPI inhibitor in cartilage. Whether it is synthesized locally by the chondrocytes or the synovial fibroblasts remains to be elucidated. Another possibility would be the diffusion of the inhibitor from the circulation into the matrix. In this case the negatively chafged proteoglycans could function as a kind of cation-exchanger to concentrate the inhibitor molecule in the matrix. Regardless of the site of synthesis, the inhibitor can play a major role in the protection of the cartilage matrix proteins against proteolytic damage by association with the target molecules. Owing to its affinity for the serine proteinases, as indicated by the kinetic data of enzyme inhibition (Thompson & Ohlsson, 1986; Burkhardt et al., 1987; Bieth, 1980) , it ought to have a strong protective potential. Further studies are needed to answer the question as to whether disturbances in concentration or function of the inhibitor contribute to cartilage degradation in diseases such as osteoarthritis or rheumatoid arthritis.
